Lifestyle factors and long-term survival of gastric cancer patients: A large bidirectional cohort study from China

Zhao, Lulu; Huang, Huang; Wang, Yang; Wang, Tong-Bo; Zhou, Hongcheng; Ma, Fuhai; Ren, Hanyun; Niu, Penghui; Zhao, Dongbing; Chen, Yingtai

doi:10.3748/wjg.v26.i14.1613

Cited by 18 publications

(13 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Established risk factors for gastric and pancreatic cancers include smoking, excess body weight, high salt intake, alcohol, physical activity, and infection by Helicobacter pylori ( American Cancer Society, 2020 ). However, studies show contrasting results, some documenting that smoking decreases survival ( Zhao et al, 2020 ) and others showing no significant association ( Trivers et al, 2005 ; Sundelöf et al, 2008 ; Ferronha et al, 2012 ). An estimated 5% of cancers in men and 11% in women are related to excess body weight ( Islami et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Dietary and Lifestyle Factors Associated with Gastric and Pancreatic Cancers: A Case-Control Study

Al-Awwad

Allehdan

Al‐Jaberi

et al. 2021

Prev. Nutr. Food Sci.

View full text Add to dashboard Cite

Gastric cancer (GC) and pancreatic cancer (PC) are the third and seventh most likely cancers to cause death worldwide. We aimed to determine the dietary and lifestyle factors of patients with GC or PC and their associated risk among Jordanians. This case-control study enrolled 587 adults (patients with PC, 101; patients with GC, 172; healthy controls, 314) between March 2015 and August 2018, who were assessed using interview-based personal and physical activity questionnaires. Multivariable logistic regression models were taken as measures for predictors of GC and PC risk. We showed that GC and PC patients had higher pre-diagnosis body-mass indexes, a greater proportion smoked and had a family history of cancer than controls. Furthermore, consumption of two snacks [odds ratios (OR)=0.44, 95% confidence intervals (CI): 0.23~0.85], three snacks (OR=0.04, 95% CI: 0.01~0.23) and no meals eaten outside (OR=0.31, 95% CI: 0.09~0.99) showed a protective effect against GC, and consumption of three snacks (OR=0.08, 95% CI: 0.02~0.40) reduced significantly the risk of PC. These results suggest that bodyweight, physical activity, smoking, and family history of cancer are among factors that affect GC and PC risk among Jordanians.

show abstract

Section: Introductionmentioning

confidence: 99%

Dietary and Lifestyle Factors Associated with Gastric and Pancreatic Cancers: A Case-Control Study

Al-Awwad

Allehdan

Al‐Jaberi

et al. 2021

Prev. Nutr. Food Sci.

View full text Add to dashboard Cite

show abstract

“…The study population was described in detail in the previous research [18,19]. Brie y, all histologically con rmed incident cases of GC diagnosed between 1998 and 2018 in the cancer center were identi ed through the China National Cancer Center Gastric Cancer Database (NCCGCDB).…”

Section: Data Source and Patient Selectionmentioning

confidence: 99%

Clinicopathological Characteristics, Survival Outcomes, and Genetic Alterations of Younger Patient With Gastric Cancer: Results From China National Cancer Center and cBioPortal

Niu

Huang

Zhao

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundSurvival outcomes of younger patients with gastric cancer (GC) remains controversial. The present study sought to explore clinicopathological characteristics, survival outcomes, and genetic alterations in the younger and older patients with GC.MethodsPatients with GC were identified from the China National Cancer Center Gastric Cancer Database (NCCGCDB) during 1998–2018. Survival analysis was conducted via Kaplan-Meier estimates and Cox proportional hazards models. Sequencing data were enrolled from the China National Cancer Center, TCGA, and MSKCC databases. ResultsA total of 1146 younger and 16988 older cases were included. Patients in the younger group were predominant in poor differentiation (53.7% versus 33.8%, P<0.0001), and pTNM stage IV (19.5% versus 11.8%, P<0.001). The 5-year overall survival (OS) of patients in NCCGCDB has noticeable increased from 1998 to 2018. Younger age was an independent prognostic factor for GC patients in pTNM stage III (P=0.014), while other stages showed no difference. Compared to the younger, older patients had a higher mutation frequency in LRP1B, GNAS, APC, KMT2D genes (all P< 0.05). In addition, although no significant difference, results of the China National Cancer Center, TCGA, and MSKCC cohorts indicated that younger patients dominated in CDH1, RHOA, and CTNNB1 mutations.ConclusionsStable proportion of younger cases and noticeable survival improvements were reported in the China National Cancer Center. Younger patients with pTNM stage III had a worse survival than older, while other tumor stages showed no difference. Furthermore, distinctive molecular characteristics were identified in younger GC patients, which might partly explain histopathological behaviors and prognosis of in this subpopulation.

show abstract

“…Gastric cancer (GC) is one of the most common malignant tumors and the fifth leading cause of cancer-related death worldwide ( 1 ). The situation is even grimmer in China, which accounts for about half of the morbidity and mortality associated with stomach disease ( 1 , 2 ). Although the age-adjusted incidence and mortality rates in gastric cancer have decreased during the last decades, the relative survival has only witnessed a modest increase compared to improvements in many other gastrointestinal cancers ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

OncoVee™-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients With Synchronous Liver Metastases: A Retrospective Cohort Analysis

Zhang

Liang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundIt is estimated that 35% of gastric cancer patients appear with synchronous distant metastases—the vast majority of patients presenting with metastatic hepatic disease. How to choose the most appropriate drugs or regimens is crucial to improve the prognosis of patients. We conducted this retrospective cohort analysis to evaluate the efficacy of OncoVee™-MiniPDX-guided treatment for these patients.MethodsGastric cancer patients with liver metastases (GCLM) were enrolled. Patients were divided into MiniPDX and control group according to their wishes. In the observation group, the OncoVee™-MiniPDX model was conducted to screen the most sensitive drug or regimens to determine the clinical administration. Meanwhile, patients were treated with regular medications in the control group according to the guidelines without the MiniPDX model. The primary endpoint was overall survival (OS), and the secondary outcomes included objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).ResultsA total of 68 patients with GCLM were included, with the observation and control groups of 21 and 47 patients, respectively. The baseline characteristics of patients were balanced between these two groups. MiniPDX drug sensitivity tests were associated with the increased use of targeted drugs when compared with the control group (33.3 vs. 0%, p=0.032). Median OS was estimated to be 9.4 (95% CI, 7.9–11.2) months and 7.9 (95% CI, 7.2–8.7) months in the observation and control group, respectively. Both univariate (control group vs. MiniPDX group: HR=2.586, 95% CI= 1.362–4.908, p=0.004) and multivariate regression analyses (Control group vs. MiniPDX group: adjusted HR (aHR)=4.288, 95% CI= 1.452–12.671, p=0.008) showed the superiority of the observation group on OS. Similarly, MiniPDX-based regiments significantly improve the PFS of these cases (median PFS 6.7 months vs. 4.2 months, aHR=2.773, 95% CI=1.532–3.983, p=0.029). ORR and DCR were also improved in MiniPDX group comparing with control group (ORR, 57.14 vs. 25.53%, p=0.029; DCR: 85.71 vs. 68.08%, p=0.035).ConclusionOncoVee™-MiniPDX model, which was used to select drugs to guide antitumor treatment, was promising to prolong survival and improve the response rate of patients with GCLM. Further well-designed studies are needed to confirm the clinical benefits of MiniPDX.

show abstract

Lifestyle factors and long-term survival of gastric cancer patients: A large bidirectional cohort study from China

Cited by 18 publications

References 50 publications

Dietary and Lifestyle Factors Associated with Gastric and Pancreatic Cancers: A Case-Control Study

Dietary and Lifestyle Factors Associated with Gastric and Pancreatic Cancers: A Case-Control Study

Clinicopathological Characteristics, Survival Outcomes, and Genetic Alterations of Younger Patient With Gastric Cancer: Results From China National Cancer Center and cBioPortal

OncoVee™-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients With Synchronous Liver Metastases: A Retrospective Cohort Analysis

Contact Info

Product

Resources

About